Treatment of thrombotic thrombocytopenic purpura

Straaten, Menno van der; Jamart, Sophie; Wens, Robert; Gottignies, Philippe; Dratwa, Max; Devriendt, Jacques
April 2005
Intensive Care Medicine;Apr2005, Vol. 31 Issue 4, p600
Academic Journal
This article focuses on the treatment of thrombotic thrombocytopenic purpura. The sometimes-autoimmune characteristics of thrombotic thrombocytopenic purpura (TTP) gives a rationale for treatment with Rituximab, a chimeric monoclonal antibody against the CD20 receptor of B-lymphocytes, and preliminary reports are very promising. The authors present a case of a patient with TTP treated with Rituximab. A 59-year-old man was hospitalised for aphasia, paresis of the inferior right facial nerve, and fever. Rituximab is very promising in the treatment of TTP with deficiency of ADAMTS13 activity and inhibitor activity.


Related Articles

  • Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Reddy, Pavan S.; Deauna-Limayo, Delva; Cook, James D.; Ganguly, Siddhartha S.; Blecke, Carol; Bodensteiner, David C.; Skikne, Barry S.; Sahud, Mervin A. // Annals of Hematology;Apr2005, Vol. 84 Issue 4, p232 

    Several reports have defined nonfamilial thrombotic thrombocytopenic purpura (TTP) as an autoimmune disorder caused by antibodies to von Willebrand’s factor-cleaving protease (vWF-CP). This raises the possibility that rituximab, a monoclonal antibody against CD20 present in B-lymphoid...

  • Gemcitabine.  // Reactions Weekly;8/11/2007, Issue 1164, p14 

    The article describes three case reports of thrombotic microangiopathy. Three patients had developed thrombotic angiopathy during administration of gemcitabine. All patients were diagnosed as having anaemia, schistocytosis, thrombocytopenia, renal insufficiency and a decreased serum haptoglobin...

  • Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion. Ziakas, Panayiotis D.; Kopterides, Petros; Voulgarelis, Michael // Current Vascular Pharmacology;Jan2010, Vol. 8 Issue 1, p51 

    Monoclonal antibodies have been developed to optimize treatment effects in various malignant and non-malignant conditions, by selectively targeting key components of the underlying pathophysiologic processes. Rituximab, a chimeric anti-CD20 antibody has revolutionized treatment of malignant...

  • Púrpura trombótica trombocitopénica. Presentación de casos y discusión. Hernández, José Domingo Torres; Toro, Luis Guillermo // MedUNAB;sep2008, Vol. 11 Issue 2, p176 

    In this paper two thrombotic thrombocytopenic purpura (TTP) are presented; first one had excellent response but second one died because had lack of AB plasma to treatment. TTP is high mortality disorder if it not suspected and do a effective treatment. Anemia associated with thrombocytopenia...

  • Púrpura trombocitopénica trombótica resistente; tratamiento con rituximab. Cruz-Hernández, Víctor; León-Tapia, Samuel; Santos-Blas, Yazmin; Acevedo-Cruz, Ana; Pérez Campos, Eduardo // Medicina Interna de Mexico;jul-ago2014, Vol. 30 Issue 4, p496 

    Thrombotic thrombocytopenic purpura belongs to the group of microangiopathic hemolytic anemia; it is characterized by fragmentation of erythrocytes and consumption of platetes. It is a very rare disease and its diagnosis is based on a pentad of symptoms: anemia, thrombocytopenia, fever,...

  • Microangiopathic Hemolytic Anemia in Metastatic Carcinoma. Lohrmann, Hans-Peter; Adam, Wolfgang; Heymer, Berno // Annals of Internal Medicine;Sep73, Vol. 79 Issue 3, p368 

    Focuses on a study that observed eight patients with metastatic carcinoma and microangiopathic hemolytic anemia. Materials and methods; Results; Discussion.

  • Rituximab Treatment for Thrombotic Thrombocytopenic Purpura Associated with Human Immunodeficiency Virus Failing Extensive Treatment with Plasma Exchange: A Report of Two Cases. Evans, Michael W.; Vaughan, Leroy B.; Giffi, Victoria S.; Zimrin, Ann B.; Hess, John R. // AIDS Patient Care & STDs;Jun2010, Vol. 24 Issue 6, p349 

    In an urban area with a 3% prevalence of HIV infection, two women presented in a 1-year period with AIDS and thrombotic thrombocytopenic purpura (TTP). TTP was diagnosed in each patient based on the presence of thrombocytopenia, schistocytes, and markedly elevated lactate dehydrogenase (LDH)...

  • Vincristine as treatment for recurrent episodes of thrombotic thrombocytopenic purpura. Ferrara, F.; Annunziata, M.; Pollio, F.; Palmieri, S.; Copia, C.; Mele, G.; Pocali, B.; Schiavone, E. M. // Annals of Hematology;Jan2002, Vol. 81 Issue 1, p7 

    The clinical course of thrombotic thrombocytopenic purpura has dramatically improved after the introduction of plasma-based therapy, including plasma exchange and plasma infusion. However, a considerable number of patients still experience relapse after initial successful treatment. In this...

  • Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE. Abdwani, R.; Mani, R. // Lupus;May2009, Vol. 18 Issue 5, p460 

    Haematological involvement occurs frequently in childhood onset systemic lupus erythematosus (SLE) with autoimmune haemolytic anaemia occurring in 10%. Conventional treatment includes high-dose steroids. Second line agents used in refractory cases include azathioprine, mycophenolate mofetil,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics